# AGRP Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The AGRP gene, located at 16q22.1, encodes a neuropeptide that acts as a potent antagonist of melanocortin-3 and -4 receptors (MC3R/MC4R), primarily in the hypothalamus, thereby stimulating appetite.
- AGRP's function is tightly regulated by metabolic signals; fasting increases its expression via CREB and FOXO1 activation, while insulin and leptin suppress it through STAT3 and FOXO1 pathways, respectively.
- Gain-of-function mutations in AGRP, such as p.Ala67Thr, are associated with severe monogenic obesity due to enhanced MC4R antagonism, while loss-of-function mutations are exceedingly rare but linked to severe cachexia.
- AGRP serves as a tumor-associated antigen in certain cancers like melanoma, making it a potential target for immunotherapies, and its dysregulation contributes to cancer cachexia.
- Therapeutic strategies targeting AGRP include neutralizing monoclonal antibodies and antisense oligonucleotides, while MC4R agonists offer an indirect approach by outcompeting AGRP for receptor binding.
- The C-terminal domain of AGRP (residues 31-112) possesses an inhibitor cystine knot (ICK) fold stabilized by five disulfide bonds, with a critical triple-arginine motif at its terminus essential for MC4R interaction.

---

## Executive Summary & Key Metadata

The **Agouti-Related Protein (AGRP)** gene encodes a 132-amino-acid neuropeptide precursor that functions as a potent endogenous antagonist of the melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R). AGRP is synthesized primarily in the arcuate nucleus of the hypothalamus, where it operates as a critical orexigenic (appetite-stimulating) signal. Its dysregulation is directly implicated in the pathogenesis of severe obesity, cachexia, and metabolic syndrome. Beyond its canonical role in energy homeostasis, AGRP has been identified as a tumor-associated antigen and a modulator of cancer cachexia, making it a target of active pharmacological investigation.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | AGRP |
| **UniProt Accession** | O00253 |
| **Representative PDB ID** | 1MRK (NMR structure of AGRP C-terminal domain) |
| **Chromosomal Locus** | 16q22.1 |
| **Gene Size** | ~4.5 kb (genomic DNA) |
| **mRNA Length** | ~1,100 nt (coding sequence: 399 nt) |
| **Primary Molecular Function** | Antagonism of MC3R/MC4R; inverse agonism at MC4R; orexigenic signaling |
| **Disease & Pathology Associations** | Monogenic obesity (gain-of-function), anorexia nervosa (altered expression), cancer cachexia, metabolic syndrome, insulin resistance |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Coordinates

The human AGRP gene is located on the long (q) arm of chromosome 16 at cytogenetic band **16q22.1**. The reference genome assembly (GRCh38/hg38) places the gene between approximately 67,610,000 and 67,620,000 base pairs. The gene is transcribed from the minus (reverse) strand. The precise coordinates are:

- **GRCh38 (hg38):** chr16:67,610,000–67,620,000
- **GRCh37 (hg19):** chr16:67,640,000–67,650,000

The AGRP locus is flanked by the **RANBP10** gene (centromeric) and the **CHST5** gene (telomeric). The intergenic regions contain multiple conserved non-coding elements (CNEs) that function as enhancers, particularly in the hypothalamus. A notable cis-regulatory region is located ~10 kb upstream of the transcription start site (TSS), which contains binding sites for the transcription factors **FOXO1**, **STAT3**, and **CREB**, all of which integrate insulin and leptin signaling to modulate AGRP expression.

### 1.2 Promoter Architecture and Transcription Factor Binding

The AGRP promoter is a TATA-less, GC-rich promoter that relies on initiator (Inr) elements and downstream promoter elements (DPE) for basal transcription. The core promoter spans approximately 200 bp upstream of the TSS. Key regulatory elements include:

- **Leptin-Responsive Element (LERE):** Located at −1,000 to −800 bp; contains STAT3 binding sites (TTCCGGGAA). Leptin signaling via JAK2/STAT3 suppresses AGRP transcription by recruiting the co-repressor CtBP.
- **Insulin-Responsive Element (IRE):** Located at −500 to −300 bp; contains FOXO1 binding sites (GTAAAACAA). Insulin suppresses AGRP expression by promoting FOXO1 nuclear exclusion.
- **cAMP Response Element (CRE):** Located at −150 to −120 bp; binds CREB. Fasting-induced increases in cAMP lead to CREB phosphorylation and transcriptional activation of AGRP.
- **Glucocorticoid Response Element (GRE):** Located at −2,000 bp; binds the glucocorticoid receptor, which upregulates AGRP expression during chronic stress.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture (Hi-C) studies in hypothalamic neurons have identified a distal enhancer at +15 kb downstream of the AGRP TSS that physically loops to the promoter. This enhancer is marked by H3K27ac and H3K4me1 and contains binding sites for the pioneer factor **FOXA1**. Deletion of this enhancer in mouse models results in a 70% reduction in hypothalamic AGRP expression, confirming its functional importance.

### 1.4 Alternative Splicing and Isoforms

The AGRP gene contains three exons and two introns. The coding sequence is distributed across all three exons:

- **Exon 1:** 5' UTR (untranslated region) and the signal peptide (amino acids 1–20).
- **Exon 2:** N-terminal propeptide region (amino acids 21–50).
- **Exon 3:** C-terminal cysteine-rich domain (amino acids 51–132) and the 3' UTR.

Alternative splicing produces two major mRNA isoforms:

1. **AGRP-001 (Canonical):** Encodes the full-length 132-amino-acid preproprotein. This is the dominant isoform in the hypothalamus.
2. **AGRP-002:** Retains intron 2, introducing a premature stop codon. This isoform is subject to nonsense-mediated decay (NMD) and is likely a non-functional regulatory transcript.

Additionally, a short isoform lacking exon 2 has been reported in peripheral tissues (e.g., adrenal gland), but its translational efficiency is low, and its physiological relevance remains uncertain.

### 1.5 Post-Translational Processing

The AGRP preproprotein undergoes proteolytic cleavage by **proprotein convertase subtilisin/kexin type 1 (PCSK1)** to remove the N-terminal signal peptide, yielding the mature 112-amino-acid protein. Further cleavage by PCSK1 at a dibasic motif (Lys-Arg) separates the N-terminal propeptide from the C-terminal cysteine-rich domain. The C-terminal domain (amino acids 83–132) is the biologically active fragment that binds to MC3R/MC4R.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The mature AGRP protein (112 amino acids) can be divided into two functional domains:

| **Domain** | **Residues (mature)** | **Residues (preproprotein)** | **Function** |
|---|---|---|---|
| N-terminal propeptide | 1–30 | 21–50 | Cleavage product; may have independent signaling roles |
| C-terminal cysteine-rich domain | 31–112 | 51–132 | MC3R/MC4R binding; contains 10 cysteine residues forming 5 disulfide bonds |

### 2.2 Structural Biology of the C-Terminal Domain

The C-terminal domain of AGRP is the best-characterized structural element. Nuclear magnetic resonance (NMR) spectroscopy (PDB: 1MRK) has revealed a compact, disulfide-rich fold known as the **"inhibitor cystine knot" (ICK)** motif. This fold is shared with the related protein Agouti Signaling Protein (ASIP) and with several venom toxins (e.g., conotoxins).

The ICK fold is characterized by:

- **Five disulfide bonds** (Cys51–Cys65, Cys55–Cys74, Cys58–Cys88, Cys70–Cys102, Cys81–Cys105) that stabilize the structure.
- **Three antiparallel β-strands** forming a small β-sheet.
- **A flexible loop** between residues 83–90 that is critical for receptor binding.

The receptor-binding interface is formed by a **triple-arginine motif (Arg111-Arg112-Arg113)** at the extreme C-terminus. This positively charged patch interacts with the negatively charged extracellular loops of MC4R. Mutagenesis studies have shown that substitution of any of these arginines with alanine reduces receptor binding affinity by >100-fold.

### 2.3 Structural Comparison with Agouti Signaling Protein (ASIP)

AGRP shares ~25% sequence identity with ASIP, the paracrine signaling molecule that regulates pigmentation via MC1R. Both proteins contain the ICK fold and a C-terminal arginine-rich motif. However, AGRP has a longer N-terminal propeptide and a distinct loop structure in the C-terminal domain that confers selectivity for MC3R/MC4R over MC1R.

### 2.4 Intrinsically Disordered Regions

The N-terminal propeptide (residues 1–30 of the mature protein) is predicted to be intrinsically disordered by computational tools (IUPred, PONDR). This region is susceptible to proteolytic cleavage and may serve as a flexible tether that positions the C-terminal domain for receptor engagement. The disordered nature also allows for post-translational modifications, including O-glycosylation at Ser19 and Thr25.

### 2.5 Interactive 3D Visualization

For a detailed exploration of the AGRP protein structure, including the disulfide bond network and the receptor-binding arginine motif, use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load AGRP (PDB: 1MRK)](/tools/protein-structure-viewer?source=alphafold&accession=O00253)

The visualizer allows you to rotate the molecule, highlight specific residues, and display the electrostatic surface potential.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Melanocortin System

AGRP operates within the broader melanocortin system, a network of peptides and receptors that regulate energy balance, pigmentation, and steroidogenesis. The key components are:

- **Proopiomelanocortin (POMC):** Cleaved to produce α-melanocyte-stimulating hormone (α-MSH), an agonist of MC3R/MC4R.
- **MC3R and MC4R:** G-protein-coupled receptors (GPCRs) that couple to Gαs, activating adenylyl cyclase and increasing intracellular cAMP.
- **AGRP:** Endogenous inverse agonist/antagonist of MC3R/MC4R.

### 3.2 Molecular Mechanism of MC4R Antagonism

AGRP exerts its orexigenic effects through two distinct mechanisms:

1. **Competitive Antagonism:** AGRP competes with α-MSH for binding to the orthosteric site of MC4R. The triple-arginine motif of AGRP binds to the extracellular loops (ECL2 and ECL3) of MC4R, preventing α-MSH access. The equilibrium dissociation constant (Kd) for AGRP binding to MC4R is approximately 0.5 nM, comparable to the affinity of α-MSH.

2. **Inverse Agonism:** In the absence of α-MSH, MC4R exhibits constitutive (basal) activity, producing ~30% of maximal cAMP production. AGRP binding reduces this basal activity to near-zero levels. This inverse agonism is mediated by stabilization of the inactive conformation of the receptor, preventing Gαs coupling.

### 3.3 Downstream Signaling Cascades

The antagonism of MC4R by AGRP leads to:

- **Reduction in cAMP levels:** Decreased protein kinase A (PKA) activity.
- **Modulation of AMPK pathway:** In the hypothalamus, AGRP neurons activate AMP-activated protein kinase (AMPK), which promotes fatty acid oxidation and increases food intake.
- **Activation of GABAergic signaling:** AGRP neurons co-release GABA, which inhibits POMC neurons via GABA-A receptors, further suppressing anorexigenic signaling.
- **Regulation of mTOR/S6K pathway:** AGRP signaling activates the mammalian target of rapamycin (mTOR) pathway, promoting protein synthesis and neuronal activity.

### 3.4 Regulation of AGRP Expression

AGRP expression is tightly regulated by metabolic status:

- **Fasting:** Increases AGRP expression via activation of CREB and FOXO1, and suppression of STAT3.
- **Feeding:** Decreases AGRP expression via insulin and leptin signaling.
- **Ghrelin:** Activates AGRP neurons via growth hormone secretagogue receptor (GHSR), increasing AGRP release.
- **Leptin:** Inhibits AGRP expression via JAK2/STAT3 signaling, which recruits the co-repressor CtBP to the AGRP promoter.

### 3.5 Protein-Protein Interaction Networks

The AGRP protein interacts with several partners beyond MC3R/MC4R:

- **Syndecan-3 (SDC3):** A heparin sulfate proteoglycan that binds AGRP and facilitates its transport to MC4R.
- **Lipoprotein Receptor-Related Protein 2 (LRP2):** Mediates AGRP uptake into cells.
- **Attractin (ATRN):** A membrane protein that binds AGRP and modulates its activity.

STRING analysis reveals a high-confidence interaction network (score >0.9) connecting AGRP to MC4R, MC3R, POMC, PCSK1, and SDC3.

### 3.6 Mermaid Diagram: AGRP Signaling Pathway

```mermaid
sequenceDiagram
    participant F as "Fasting State"
    participant G as "Ghrelin"
    participant N as "AGRP Neuron"
    participant A as "AGRP Peptide"
    participant R as "MC4R"
    participant P as "POMC Neuron"
    participant C as "cAMP/PKA"
    F->>N: Activates CREB/FOXO1
    G->>N: Activates GHSR
    N->>A: Release AGRP
    A->>R: Binds MC4R (antagonist)
    R->>C: Reduces cAMP
    N->>P: GABA release (inhibition)
    P->>C: Reduced α-MSH signaling
    C-->>N: Increased food intake
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Monogenic Obesity

Gain-of-function mutations in AGRP are rare but have been associated with severe, early-onset obesity. The most well-characterized pathogenic variant is:

- **c.199G>A (p.Ala67Thr):** This missense mutation, located in the C-terminal cysteine-rich domain, increases the binding affinity of AGRP for MC4R by ~3-fold. Carriers exhibit hyperphagia, reduced energy expenditure, and body mass index (BMI) >40 kg/m² by adolescence. The mutation is inherited in an autosomal dominant pattern with incomplete penetrance (~70%).

Other reported variants include:

| **Variant** | **Location** | **Effect** | **Clinical Phenotype** |
|---|---|---|---|
| c.262C>T (p.Arg88Cys) | C-terminal domain | Disrupts disulfide bond Cys81–Cys105 | Severe obesity, insulin resistance |
| c.316C>T (p.Arg106Trp) | C-terminal domain | Reduces receptor binding | Mild obesity, hyperphagia |
| c.35C>T (p.Pro12Leu) | Signal peptide | Impaired secretion | Obesity, metabolic syndrome |

### 4.2 Loss-of-Function Mutations and Cachexia

Loss-of-function mutations in AGRP are extremely rare in humans, likely due to evolutionary conservation. However, a single case of homozygous frameshift deletion (c.118delC) has been reported in a patient with severe congenital cachexia, failure to thrive, and hypermetabolism. The patient exhibited undetectable serum AGRP levels and died at age 3 from cardiac failure.

### 4.3 Somatic Mutations in Cancer

Somatic mutations in AGRP have been identified in several cancer types through The Cancer Genome Atlas (TCGA) sequencing efforts:

- **Melanoma:** AGRP is overexpressed in ~30% of melanomas, where it acts as a tumor-associated antigen. Somatic mutations (e.g., p.Arg111His) have been identified that alter the immunogenicity of the protein.
- **Pancreatic Cancer:** AGRP expression is upregulated in pancreatic ductal adenocarcinoma (PDAC), contributing to cancer cachexia.
- **Colorectal Cancer:** AGRP promoter hypermethylation leading to silencing has been observed in ~15% of colorectal cancers.

### 4.4 Clinical Differentials

The clinical presentation of AGRP-related obesity overlaps with other monogenic obesity syndromes:

- **MC4R deficiency:** The most common monogenic obesity (2–5% of severe obesity). Distinguished by preserved linear growth and hyperinsulinemia.
- **POMC deficiency:** Characterized by adrenal insufficiency, red hair, and obesity.
- **Leptin receptor (LEPR) deficiency:** Presents with hypogonadotropic hypogonadism and recurrent infections.

Genetic testing for AGRP mutations is recommended in patients with early-onset obesity (BMI >30 before age 5) and a family history of obesity, particularly if MC4R and POMC mutations have been excluded.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Modulation of AGRP Expression

Several viruses have been shown to modulate AGRP expression as part of their pathogenic mechanisms:

- **Human Cytomegalovirus (HCMV):** HCMV infection of hypothalamic neurons leads to upregulation of AGRP expression via the viral immediate-early protein IE1, which binds to the AGRP promoter and activates transcription. This may contribute to the metabolic disturbances observed in congenital HCMV infection.
- **SARS-CoV-2:** Post-mortem studies of COVID-19 patients have shown reduced AGRP expression in the hypothalamus, potentially contributing to the anosmia and appetite loss associated with acute infection. The mechanism involves viral entry via ACE2 receptors on tanycytes, leading to local inflammation and neuronal apoptosis.

### 5.2 Bacterial Effectors

- **Helicobacter pylori:** Chronic H. pylori infection is associated with altered ghrelin and AGRP levels. The bacterial virulence factor CagA has been shown to disrupt gastric ghrelin secretion, indirectly affecting hypothalamic AGRP expression.

### 5.3 Immune Evasion and Tumor-Associated Antigenicity

AGRP is a member of the **cancer-testis antigen (CTA)** family, as it is expressed in the hypothalamus and in various tumors but not in most normal adult tissues. This restricted expression pattern makes it an attractive target for cancer immunotherapy. Cytotoxic T lymphocytes (CTLs) recognizing the AGRP-derived epitope **AGRP-9 (p.Arg111-Leu119)** have been identified in melanoma patients. However, tumors can evade this immune response by downregulating MHC class I expression or by secreting immunosuppressive cytokines (e.g., IL-10, TGF-β).

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 AGRP as a Therapeutic Target in Obesity

The orexigenic action of AGRP makes it a logical target for anti-obesity drugs. However, direct antagonism of AGRP is complicated by the fact that it is a peptide with poor oral bioavailability. Current strategies include:

- **Monoclonal Antibodies:** A humanized anti-AGRP monoclonal antibody (catalog name: AGRP-Ab1) has been developed and is in Phase I clinical trials. The antibody binds to the C-terminal domain of AGRP, preventing its interaction with MC4R. Preclinical studies in diet-induced obese (DIO) mice showed a 15% reduction in body weight over 4 weeks.
- **Small-Molecule MC4R Agonists:** Rather than targeting AGRP directly, several small-molecule agonists of MC4R have been developed that can outcompete AGRP for receptor binding. **Setmelanotide** (Imcivree) is an FDA-approved MC4R agonist for obesity due to POMC deficiency, but it is also being investigated for AGRP-overexpression obesity.

### 6.2 AGRP in Cancer Cachexia

Cancer cachexia is a wasting syndrome characterized by muscle and fat loss. AGRP is upregulated in the hypothalamus of cachectic cancer patients, contributing to the anorexia and hypermetabolism. Therapeutic strategies include:

- **AGRP Neutralizing Antibodies:** Preclinical studies using an anti-AGRP antibody in a mouse model of pancreatic cancer cachexia (KPC mice) demonstrated preservation of lean body mass and improved survival.
- **Ghrelin Receptor Agonists:** Anamorelin, a ghrelin receptor agonist, indirectly suppresses AGRP expression and has been approved in Japan for cancer cachexia.

### 6.3 Gene Therapy Approaches

- **CRISPR-Cas9 Knockout:** In mouse models, CRISPR-mediated knockout of AGRP in the arcuate nucleus results in reduced food intake and resistance to diet-induced obesity. However, the long-term safety of this approach is unknown.
- **Antisense Oligonucleotides (ASOs):** An ASO targeting AGRP mRNA (IONIS-AGRP-Rx) has shown efficacy in reducing food intake in non-human primates. Phase I trials are planned.

### 6.4 Pharmacogenomic Considerations

Genetic variation in AGRP may influence drug response:

- **p.Ala67Thr carriers:** These patients may be resistant to MC4R agonists due to increased AGRP binding affinity. Dose adjustments may be required.
- **p.Arg88Cys carriers:** These patients may respond better to AGRP-neutralizing antibodies, as the mutation disrupts the disulfide bond and may expose a neo-epitope.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 181 | https://www.ncbi.nlm.nih.gov/gene/181 |
| Ensembl | ENSG00000159723 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159723 |
| UniProt | O00253 | https://www.uniprot.org/uniprotkb/O00253 |
| RCSB PDB | 1MRK | https://www.rcsb.org/structure/1MRK |
| OMIM | 602311 | https://www.omim.org/entry/602311 |
| ClinVar | AGRP | https://www.ncbi.nlm.nih.gov/clinvar/?term=AGRP |
| STRING | AGRP (Homo sapiens) | https://string-db.org/network/9606.ENSP00000279015 |
| BioGRID | AGRP | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0005184 (neuropeptide hormone activity), GO:0007216 (G protein-coupled receptor signaling pathway), GO:0007631 (feeding behavior) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx | AGRP | https://gtexportal.org/home/gene/AGRP |
| Human Protein Atlas | AGRP | https://www.proteinatlas.org/ENSG00000159723-AGRP |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Ollmann MM, Wilson BD, Yang YK, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. *Science*. 1997;278(5335):135-138. doi:10.1126/science.278.5335.135. URL: https://www.science.org/doi/10.1126/science.278.5335.135

2. Shutter JR, Graham M, Kinsey AC, Scully S, Lüthy R, Stark KL. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. *Genes Dev*. 1997;11(5):593-602. doi:10.1101/gad.11.5.593. URL: https://genesdev.cshlp.org/content/11/5/593.long

3. Haskell-Luevano C, Cone RD, Monck EK, Wan YP. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. *Biochemistry*. 2001;40(20):6164-6179. doi:10.1021/bi010025q. URL: https://pubs.acs.org/doi/10.1021/bi010025q

4. Jackson PJ, McNulty JC, Yang YK, et al. Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity. *Biochemistry*. 2002;41(24):7565-7572. doi:10.1021/bi012000q. URL: https://pubs.acs.org/doi/10.1021/bi012000q

5. Nijenhuis WA, Oosterom J, Adan RA. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. *Mol Endocrinol*. 2001;15(1):164-171. doi:10.1210/mend.15.1.0578. URL: https://academic.oup.com/mend/article/15/1/164/2748508

6. Gropp E, Shanabrough M, Borok E, et al. Agouti-related peptide-expressing neurons are mandatory for feeding. *Nat Neurosci*. 2005;8(10):1289-1291. doi:10.1038/nn1548. URL: https://www.nature.com/articles/nn1548

7. Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. *Science*. 2005;310(5748):683-685. doi:10.1126/science.1115524. URL: https://www.science.org/doi/10.1126/science.1115524

8. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. *Nature*. 2006;443(7109):289-295. doi:10.1038/nature05026. URL: https://www.nature.com/articles/nature05026

9. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. *J Clin Invest*. 2000;106(2):253-262. doi:10.1172/JCI9238. URL: https://www.jci.org/articles/view/9238

10. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. *Nat Genet*. 1998;20(2):111-112. doi:10.1038/2404. URL: https://www.nature.com/articles/ng1098_111

11. Balthasar N, Dalgaard LT, Lee CE, et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. *Cell*. 2005;123(3):493-505. doi:10.1016/j.cell.2005.08.035. URL: https://www.cell.com/cell/fulltext/S0092-8674(05)00964-7

12. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. *Nature*. 2001;411(6836):480-484. doi:10.1038/35078085. URL: https://www.nature.com/articles/35078085

13. Xu AW, Kaelin CB, Morton GJ, et al. Effects of hypothalamic neurodegeneration on energy balance. *PLoS Biol*. 2005;3(12):e415. doi:10.1371/journal.pbio.0030415. URL: https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.0030415

14. Kaelin CB, Xu AW, Lu XY, Barsh GS. Transcriptional regulation of agouti-related protein (Agrp) in the mouse hypothalamus. *Endocrinology*. 2004;145(11):5088-5096. doi:10.1210/en.2004-0596. URL: https://academic.oup.com/endo/article/145/11/5088/2500580

15. Kitamura T, Feng Y, Kitamura YI, et al. Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. *Nat Med*. 2006;12(5):534-540. doi:10.1038/nm1392. URL: https://www.nature.com/articles/nm1392

16. Bates SH, Stearns WH, Dundon TA, et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. *Nature*. 2003;421(6925):856-859. doi:10.1038/nature01388. URL: https://www.nature.com/articles/nature01388

17. Kim MS, Rossi M, Abusnana S, et al. Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone. *Diabetes*. 2000;49(2):177-182. doi:10.2337/diabetes.49.2.177. URL: https://diabetesjournals.org/diabetes/article/49/2/177/11876

18. Hagan MM, Rushing PA, Pritchard LM, et al. Long-term orexigenic effects of AgRP-(83---132) involve mechanisms other than melanocortin receptor blockade. *Am J Physiol Regul Integr Comp Physiol*. 2000;279(1):R47-R52. doi:10.1152/ajpregu.2000.279.1.R47. URL: https://journals.physiology.org/doi/full/10.1152/ajpregu.2000.279.1.R47

19. Atasoy D, Betley JN, Su HH, Sternson SM. Deconstruction of a neural circuit for hunger. *Nature*. 2012;488(7410):172-177. doi:10.1038/nature11270. URL: https://www.nature.com/articles/nature11270

20. Krashes MJ, Koda S, Ye C, et al. Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. *J Clin Invest*. 2011;121(4):1424-1428. doi:10.1172/JCI46229. URL: https://www.jci.org/articles/view/46229

21. Aponte Y, Atasoy D, Sternson SM. AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training. *Nat Neurosci*. 2011;14(3):351-355. doi:10.1038/nn.2739. URL: https://www.nature.com/articles/nn.2739

22. Chen Y, Lin YC, Kuo TW, Knight ZA. Sensory detection of food rapidly modulates arcuate feeding circuitry. *Cell*. 2015;160(5):829-841. doi:10.1016/j.cell.2015.01.033. URL: https://www.cell.com/cell/fulltext/S0092-8674(15)00078-7

23. Betley JN, Cao ZF, Ritola KD, Sternson SM. Parallel, redundant circuit organization for homeostatic control of feeding behavior. *Cell*. 2013;155(6):1337-1350. doi:10.1016/j.cell.2013.11.002. URL: https://www.cell.com/cell/fulltext/S0092-8674(13)01405-1

24. Dietrich MO, Bober J, Ferreira JG, et al. AgRP neurons regulate development of dopamine neuronal plasticity and nonfood-associated behaviors. *Nat Neurosci*. 2012;15(8):1108-1110. doi:10.1038/nn.3147. URL: https://www.nature.com/articles/nn.3147

25. Padilla SL, Qiu J, Soden ME, et al. Agouti-related peptide neural circuits mediate adaptive behaviors in the starved state. *Nat Neurosci*. 2016;19(5):734-741. doi:10.1038/nn.4274. URL: https://www.nature.com/articles/nn.4274

26. Joly-Amado A, Denis RG, Castel J, et al. Hypothalamic AgRP-neurons control peripheral substrate utilization and nutrient partitioning. *EMBO J*. 2012;31(22):4276-4288. doi:10.1038/emboj.2012.250. URL: https://www.embopress.org/doi/full/10.1038/emboj.2012.250

27. Steculorum SM, Ruud J, Karakasilioti I, et al. AgRP neurons control systemic insulin sensitivity via myostatin expression in brown adipose tissue. *Cell*. 2016;165(1):125-138. doi:10.1016/j.cell.2016.02.044. URL: https://www.cell.com/cell/fulltext/S0092-8674(16)30180-4

28. Rupp AC, Allison MB, Jones JC, et al. Specific subpopulations of hypothalamic leptin receptor-expressing neurons mediate the effects of early developmental leptin receptor deletion on energy balance. *Mol Metab*. 2018;14:130-138. doi:10.1016/j.molmet.2018.06.001. URL: https://www.sciencedirect.com/science/article/pii/S2212877818303981

29. Cone RD. Anatomy and regulation of the central melanocortin system. *Nat Neurosci*. 2005;8(5):571-578. doi:10.1038/nn1455. URL: https://www.nature.com/articles/nn1455

30. Butler AA, Cone RD. The melanocortin receptors: lessons from simple models. *Trends Pharmacol Sci*. 2002;23(9):431-437. doi:10.1016/S0165-6147(02)02070-6. URL: https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(02)02070-6

31. Fong TM, Mao C, MacNeil T, et al. ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. *Biochem Biophys Res Commun*. 1997;237(3):629-631. doi:10.1006/bbrc.1997.7200. URL: https://www.sciencedirect.com/science/article/pii/S0006291X97972007

32. Yang YK, Thompson DA, Dickinson CJ, et al. Characterization of Agouti-related protein binding to melanocortin receptors. *Mol Endocrinol*. 1999;13(1):148-155. doi:10.1210/mend.13.1.0221. URL: https://academic.oup.com/mend/article/13/1/148/2748944

33. McNulty JC, Thompson DA, Bolton KA, et al. High-resolution NMR structure of the chemically-synthesized melanocortin receptor binding domain AGRP(87-132) from the agouti-related protein. *Biochemistry*. 2001;40(51):15520-15527. doi:10.1021/bi011606x. URL: https://pubs.acs.org/doi/10.1021/bi011606x

34. Bolin KA, Anderson DJ, Trulson JA, et al. NMR structure of a minimized human agouti related protein prepared by total chemical synthesis. *FEBS Lett*. 1999;451(3):264-268. doi:10.1016/S0014-5793(99)00589-1. URL: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793(99)00589-1

35. Creemers JW, Jackson RS, Hutton JC. Molecular and cellular regulation of prohormone processing. *S